Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047840 · ClinicalTrials.gov registry record · Phase 2
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT00047840 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 129 participants.
The verdict
NCT00047840, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG ZD6474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047840
The ClinicalTrials.gov registry entry for NCT00047840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00047840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047840 about?
NCT00047840 is a clinical study titled "This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.". The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
What is the current status of trial NCT00047840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2002-10. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00047840?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), ZD6474 (DRUG).
Who is sponsoring clinical trial NCT00047840?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.